The growth of the global infliximab drug market is driven by the rising number of rheumatoid arthritis cases. The prevalence of rheumatoid arthritis disease is likely to grow at a CAGR of 1.0% in the forecast period of 2023-2031.
Infliximab is administered through intravenous infusion and is usually given every 4-8 weeks, depending on the condition being treated. The drug is typically used in patients who have not responded to other treatments, such as corticosteroids, immunosuppressants, or non-steroidal anti-inflammatory drugs (NSAIDs).
In addition to its primary uses, infliximab is also being studied for the treatment of other autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus (SLE). The drug has also been used off-label to treat other inflammatory conditions, such as uveitis (inflammation of the eye), pyoderma gangrenosum (a rare skin disorder), and hidradenitis suppurativa (a chronic skin condition).
Crohn's disease and ulcerative colitis are the major indications for infliximab, accounting for over 50% of the market share. However, the market is also driven by the growing use of infliximab for the treatment of rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Hospitals are the largest distribution channel for infliximab, accounting for over 60% of the market share.
North America dominates the infliximab drug market, accounting for over 40% of the global market share. The high prevalence of autoimmune diseases in the region, coupled with the presence of a well-established healthcare infrastructure, is driving market growth. Europe is the second-largest market for infliximab, with the increasing adoption of biologics and the growing prevalence of autoimmune diseases driving market growth.
The Asia Pacific region is expected to witness significant growth during the forecast period, owing to the increasing prevalence of autoimmune diseases in the region and the rising healthcare expenditure. The growing awareness about the benefits of biologics and the availability of new treatment options are also expected to contribute to market growth.
Infliximab Drug Market: Introduction
Infliximab is a monoclonal antibody that is used to treat autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, and ankylosing spondylitis. The drug works by binding to tumor necrosis factor-alpha (TNF-a), a protein that contributes to inflammation, and inhibiting its activity. Infliximab is administered through intravenous infusion and is usually given every 4-8 weeks depending on the condition being treated.Infliximab Drug Market- Application and Uses
Infliximab is a monoclonal antibody that is primarily used to treat autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, and ankylosing spondylitis. These diseases are characterized by an overactive immune system that attacks healthy tissues in the body, leading to inflammation and tissue damage. Infliximab works by binding to and neutralizing a protein called tumor necrosis factor-alpha (TNF-a), which is a key contributor to inflammation in these diseases.Infliximab is administered through intravenous infusion and is usually given every 4-8 weeks, depending on the condition being treated. The drug is typically used in patients who have not responded to other treatments, such as corticosteroids, immunosuppressants, or non-steroidal anti-inflammatory drugs (NSAIDs).
In addition to its primary uses, infliximab is also being studied for the treatment of other autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus (SLE). The drug has also been used off-label to treat other inflammatory conditions, such as uveitis (inflammation of the eye), pyoderma gangrenosum (a rare skin disorder), and hidradenitis suppurativa (a chronic skin condition).
Infliximab Drug Market Segmentations
The market can be categorised into product type, route of administration, application, distribution channel, and region.Market Breakup by Product Type
- Brands Drugs
- Generic Drugs
Market Breakup by Route of Administration
- Oral
- Parenteral
- Topical
- Transdermal
- Rectal
Market Breakup by Application
- Rheumatoid Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Psoriasis
Market Breakup by Distribution Channel
- Hospital-based Pharmacies
- Online Pharmacies
- Retail Pharmacies
Infliximab Drug Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Infliximab Drug Market Scenario
The global infliximab drug market is expected to witness moderate growth in the coming years, driven by the increasing prevalence of autoimmune diseases and the growing demand for biologics. The market is highly competitive, with several multinational companies and small and medium-sized enterprises operating in the market.Crohn's disease and ulcerative colitis are the major indications for infliximab, accounting for over 50% of the market share. However, the market is also driven by the growing use of infliximab for the treatment of rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Hospitals are the largest distribution channel for infliximab, accounting for over 60% of the market share.
North America dominates the infliximab drug market, accounting for over 40% of the global market share. The high prevalence of autoimmune diseases in the region, coupled with the presence of a well-established healthcare infrastructure, is driving market growth. Europe is the second-largest market for infliximab, with the increasing adoption of biologics and the growing prevalence of autoimmune diseases driving market growth.
The Asia Pacific region is expected to witness significant growth during the forecast period, owing to the increasing prevalence of autoimmune diseases in the region and the rising healthcare expenditure. The growing awareness about the benefits of biologics and the availability of new treatment options are also expected to contribute to market growth.
Key Players in the Global Infliximab Drug Market
The report gives an in-depth analysis of the key players involved in the infliximab drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:- Zydus Lifesciences Ltd
- Pfizer Inc
- Samsung Biologics Co., Ltd
- Celltrion Healthcare Co., Ltd
- Novartis AG (Sandoz)
- AbbVie Inc
- Epirus Biopharmaceuticals, Inc
- Janssen Biotech, Inc
- NAPP Pharmaceuticals Ltd
- Nippon Kayaku Seizo Co., Ltd
- Alvogen Pharma Inc
Table of Contents
1 Preface
4 Global Infliximab Drug Overview
5 Patient Profile
6 Current Scenario Evaluation and Regulatory Framework
7 Challenges and Unmet Need
8 Global Infliximab Drug Market
9 North America Infliximab Drug Market
10 Europe Infliximab Drug Market
11 Asia Pacific Infliximab Drug Market
12 Latin America Infliximab Drug Market
13 Middle East and Africa Infliximab Drug Market
14 Global Infliximab Drug Market Dynamics
15 Supplier Landscape
16 Pricing Models and Strategies (Additional Insight)
17 Global Infliximab Drug Market- Distribution Model (Additional Insight)
Companies Mentioned
- Zydus Cadila
- Pfizer
- Samsung Bioepis
- Celltrion
- Sandoz
- AbbVie
- Hospira
- Epirus Biopharmaceuticals
- Janssen Biotech, Inc.
- NAPP Pharmaceuticals
- Nippon Kayaku
- Alvogen
Methodology
LOADING...
Related Reports
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024
- Report
- 250 Pages
- Global
From
From
Ankylosing Spondylitis / AxSpA in the United States: Understanding the AS / AxSpA Patient Experience
- Report
- 138 Pages
- United States
Psoriasis in the United States: Key Insights into Treatment Awareness & Satisfaction
- Report
- 113 Pages
- United States
Biosimilar Monoclonal Antibodies Global Market Report 2024
- Report
- 250 Pages
- Global
From
About the Infliximab Market
Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
